Stock News and Filings Feed


Add SYNGENE
to your dashboard

Asian markets lower after Dow Jones hits over 22,000 mark

2017-08-03 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

Syngene International expands research collaboration with Amgen

2017-07-28 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

Biocon posts 51% drop in net profit at Rs 81 crore in Q1

2017-07-27 moneycontrol
Biocon on Thursday said net profit declined 51 percent in the quarter ended June owing to the combined impact of a stronger rupee, GST and the one-time impact in the first quarter of the previous fiscal on account of the transition to IndAS.

Syngene International's Q1FY18 standalone net profit rises 3.7% yoy to Rs.62 crore : Misses Estimates

2017-07-27 indiainfoline
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

Growth Expectations Driving Emerging Markets

2017-07-20 seekingalpha
After a very creditable first quarter, emerging markets equities - as represented by the benchmark Morgan Stanley Capital International (MSCI) Emerging Markets Index1 - consolidated and built upon that period to achieve a gain of 18.27% for the first half of 2017. For the asset class as a whole, stronger performance can be traced to both the dissipation of a number of potentially negative factors and a solid underpinning of better earnings growth and significantly better free cash flow generation.

Sensex snaps 4-day gains; Nifty fails to hold 9900 but see stellar 2% weekly rally

2017-07-14 moneycontrol
The market failed to extend the rally on Friday as investors preferred profit booking after the Sensex added 677 points in the previous four consecutive sessions, and also looked for more corporate earnings.

Syngene International Limited - Results

2017-06-30 feedproxy.google

Erythropoietin (EPO) Drugs Market is expected to reach USD 17.4 billion by 2025

2017-06-20 prnewswire
The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cancer resulting in anemia is a major growth driver of this market. According to the statistics published by the National Heart, Lung, and Blood Institute of the U.S. Department of Health & Human Services, over 3 million people are affected by anemia every year and this number is expected to increase over the forecast period.

Eris Lifesciences plans to launch Rs2,000 crore IPO in June

2017-06-01 livemint
The IPO launch will see private equity investor ChrysCapital sell all of its stake in Eris Lifesciences

IOC, Rural Electrification rise on MSCI index addition

2017-05-16 thehindubusinessline
Shares of Indian Oil Corp Ltd and Rural Electrification Corp rose 1-1.2 per cent, while drug-maker Divi's Laboratories Ltd fell 0.4 per cent.

Syngene International falls 4.5% led by poor Q4 numbers

2017-04-28 moneycontrol
Shares of Syngene International fell 4.5 percent intraday Friday led by poor Q4 numbers where the company's profit down 0.8 percent at Rs 78.4 crore versus Rs 79 crore (Y-o-Y).

Syngene International slips over 4%

2017-04-28 indiainfoline
Syngene International Limited is a contract research company. The company is engaged in providing contract research and manufacturing services in early-stage drug discovery and development, to pharmaceutical and biotechnology companies.

Biocon March quarter profit drops 61.7% to Rs127.5 crore

2017-04-27 livemint
Mumbai: Biocon Ltd on Thursday reported a consolidated net profit of Rs127.5 crore in the quarter ended March, down 61.7% on a high base of last year when the company has certain one-off gains.

Fintel IR - Find the Right Investors for Your Company, Instantly!

Fintel IR combines the comprehensive Fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy. Learn more now!